Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma
Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma
复制标题
DOI：
10.1182/blood-2011-12-390823
复制
发表时间：
2012-11-01
期刊：
影响因子：
20.3
通讯作者：
Mueller, Nancy E.
中科院分区：
文献类型：
--
作者：
Levin, Lynn I.;Chang, Ellen T.;Mueller, Nancy E.
诊断前抗EB病毒(EBV)血清学特征的改变与霍奇金淋巴瘤的风险增加有关。目前尚不清楚这种非典型模式是否可以通过检测肿瘤细胞中的EBV来进一步细分霍奇金淋巴瘤的风险。对128例霍奇金淋巴瘤病例和368例来自现役军人和美国国防部血清库存档血清的配对对照进行了嵌套病例对照研究，以确定一组抗EBV抗体效价在EBV+和EBV-霍奇金淋巴瘤中是否存在差异。在40例EBV+霍奇金淋巴瘤患者和配对对照组中，抗EBV VCA抗体滴度升高(相对风险=3.1；95%可信区间1.1-8.7)和抗EBNA-1/抗-EBNA-2抗体比率1.0(相对风险=4.7；95%可信区间1.6-13.8)显著增加风险。相比之下，在88例EBV-霍奇金淋巴瘤患者中，与其匹配的对照组相比，没有发现显著的相关性。在病例-病例分析中，EBV+疾病与低抗EBNA-1/抗-EBNA-2抗体比率显著相关。对EBV潜伏抗原的这种独特的血清学反应表明，在其他临床环境中，免疫功能障碍与发生EBV+而不是EBV-霍奇金淋巴瘤的风险增加有关。(血。2012年；120(18)：3750-3755)
An altered anti-Epstein-Barr virus (EBV) serologic profile preceding diagnosis is associated with an increased risk of Hodgkin lymphoma. It is unknown whether this atypical pattern predicts Hodgkin lymphoma risk further subdivided by determination of EBV in tumor cells. A nested case-control study of 128 incident Hodgkin lymphoma cases and 368 matched controls from active-duty military personnel with archived serum in the US Department of Defense Serum Repository was conducted to determine whether a panel of anti-EBV antibody titers differed in EBV+ and EBV- Hodgkin lymphoma. Among 40 EBV+ Hodgkin lymphoma cases and matched controls, statistically significant increased risks were associated with elevated anti-EBV VCA IgG antibody titers (relative risk = 3.1; 95% confidence interval [CI], 1.1-8.7), and an anti-EBNA-1/anti-EBNA-2 antibody ratio 1.0 (relative risk = 4.7; 95% CI, 1.6-13.8). In contrast, no significant associations were found among 88 EBV- Hodgkin lymphoma cases relative to their matched controls. In case-case analysis, EBV+ disease was significantly associated with a low anti-EBNA-1/anti-EBNA-2 antibody ratio. This distinctive serologic response to EBV latent antigens, indicative of immune dysfunction in other clinical settings, is associated with an increased risk of developing EBV+ but not EBV- Hodgkin lymphoma. (Blood. 2012; 120(18):3750-3755)